JLE

Hématologie

MENU

Place de la maladie résiduelle dans la prise en charge des leucémies aiguës myéloïdes Volume 25, supplément 2, Juin 2019

  • [1] Donhner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152. 12
  • [2] Papaemmanuil E., Gerstung M., Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209-2221. 23
  • [3] Hourigan C.S., Gale R.P., Gormley N.J., Ossenkoppele G.J., Walter R.B. Measurable residual disease testing in acute myeloidleukaemia. Leukemia. 2017;31:1482-1490.
  • [4] Grimwade D., Freeman S.D. Defining minimal residual disease in acute myeloid leukemia : which platforms are ready for “prime time”? Hematology Am Soc Hematol Educ Program. 2014;2014:222-233.
  • [5] Chen X., Wood B.L. Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities. Blood Rev. 2017;31:63-75. 2
  • [6] Gabert J., Beillard E., van der Velden V.H.J. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17:2318-2357. 12
  • [7] Beillard E., Pallisgaard N., van der Velden V.H.J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia. 2003;17:2474-2486. 12
  • [8] Cilloni D., Renneville A., Hermitte F. Realtime quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195-5201. 31
  • [9] Schuurhuis G.J., Heuser M., Freeman S. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018;131:1275-1291. 12
  • [10] Meyer C., Burmeister T., Gröger D. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273-284. 10.1038/leu.2017.213 2
  • [11] Ferret Y., Boissel N., Helevaut N. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica. 2018;103:822-829. 10.3324/haematol.2017.183525 5
  • [12] Jongen-Lavrencic M., Grob T., Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189-1199. 10.1056/NEJMoa1716863 13
  • [13] Thol F., Gabdoulline R., Liebich A. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703-1713. 10.1182/blood-2018-02-829911 16
  • [14] Debarri H., Lebon D., Roumier C. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6:42345-42353. 10.18632/oncotarget.5645 39
  • [15] Genovese G., Kähler A.K., Handsaker R.E. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477-2487. 26
  • [16] Jaiswal S., Fontanillas P., Flannick J. Age related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488-2498. 26
  • [17] Ivey A., Hills R.K., Simpson M.A. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422-433. UK National Cancer Research Institute AML Working Group5
  • [18] Balsat M., Renneville A., Thomas X. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35:185-193. 2
  • [19] Willekens C., Blanchet O., Renneville A. Prospective longterm minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 2016;101:328-335. French AML Intergroup3
  • [20] Döhner H., Estey E., Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447. 4
  • [21] Ossenkoppele G.J., van de Loosdrecht A.A., Schuurhuis G.J. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol. 2011;153:421-436. 4
  • [22] San Miguel J.F., Martìnez A., Macedo A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90:2465-2470. 6
  • [23] Van Gassen S., Callebaut B., Van Helden M.J. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015;87:636-645. 7
  • [24] van der Maaten L., Hinton G. Visualizing data using t-SNE. J Mach Learn Res. 2008;9:2579-2605.
  • [25] Terwijn M., Zeijlemaker W., Kelder A. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587. 9
  • [26] Grimwade D., Jovanovic J.V., Hills R.K. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? Best Pract Res Clin Haematol. 2014;27:53-61. 1
  • [27] Grimwade D., Jovanovic J.V., Hills R.K. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650-3658. 22
  • [28] Platzbecker U., Avvisati G., Cicconi L. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35:605-612. 6
  • [29] Jourdan E., Boissel N., Chevret S. Prospective evaluation of gene mutations and minimal residual disease (MRD) in patients with core binding factor acute myeloid leukemia (CBF-AML). Blood. 2013;121:2213-2223. 10.1182/blood-2012-10-462879 12
  • [30] Yin J.A., O’Brien M.A., Hills R.K., Daly S.B., Wheatley K., Burnett A.K. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826-2835. 14
  • [31] Terwijn M., van Putten W.L.J., Kelder A. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889-3897. 31
  • [32] Lambert J., Lambert J., Thomas X. Early detection of WT1 minimal RESIDUAL disease predicts outcome in acute myeloid leukemia and identify patients with high risk of relapse independently of allogeneic stem cell transplantation. Blood. 2017;130. Supplement 1
  • [33] Buckley S.A., Wood B.L., Othus M. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865-873. 5
  • [34] Araki D., Wood B.L., Othus M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329-336. 4
  • [35] Zhou Y., Othus M., Araki D. Pre- and posttransplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456-1464. 7
  • [36] Alizadeh M., Bernard M., Danic B. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002;99:4618-4625. 12
  • [37] Maas F., Schaap N., Kolen S. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia. 2003;17:621-629. 3
  • [38] Duléry R., Nibourel O., Gauthier J. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52:539-543. 10.1038/bmt.2016.318 4
  • [39] Bradbury C., Houlton A.E., Akiki S. Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia. Leukemia. 2015;29:988-991. 4
  • [40] Prebet T., Bertoli S., Delaunay J. Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica. 2014;99:e185-e187. 10
  • [41] Lambert J., Lambert J., Nibourel O. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicine. Oncotarget. 2014;5:6280-6288. 15